继发性高脂血症的药物治疗进展

Strategies and Advances in the Treatment of Secondary Hyperlipidemia

他汀类药物是治疗高脂血症、预防心血管事件发生的一线药物。但有很大一部分高脂血症患者,特别是继发性高脂血症患者,在接受他汀单药治疗后不能达到低密度脂蛋白胆固醇目标值。对于那些继发于代谢综合征、糖尿病、肾脏病以及艾滋病等疾病的高脂血症患者仍然残存心血管事件风险,这可能与低水平高密度脂蛋白胆固醇、高三酰甘油水平有关。因此,需采取其他降脂药物与他汀类药物联合应用来达到预防心血管事件风险的目的。

Statins are first-line drugs for the treatment of hyperlipidemia and the prevention of cardiovascular events. However, there are still a large percent of patients with hyperlipidemia, especially those with secondary hyperlipidemia, who cannot attain standard low-density lipoprotein cholesterol targets with statins monotherapy. Possibly due to low high-density lipoprotein cholesterol or high triglycerides, high risk stiU remains in those with mixed hyperlipidemia secondary to the meta- bolic syndrome, diabetes, renal diseases and HIV infection, etc. Thus, combinations of statins and other lipid-lowering drugs seem to be more effective for these patients.